Keenova Therapeutics plc clinical trials

Also known as Mallinckrodt, MNK.

The registry lists 247 studies whose lead sponsor is Keenova Therapeutics plc or one of 11 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 247. Browse all 247 →

• Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT)Not yet recruitingNCT07846280Phase 3

  Sponsor listed in the registry: Endo USA Inc., a Keenova Therapeutics Company

• Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)RecruitingNCT07759362Phase 3

  Sponsor listed in the registry: Endo USA Inc., a Keenova Therapeutics Company

• Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)CompletedNCT06151197Phase 3

  Sponsor listed in the registry: Endo USA Inc., a Keenova Therapeutics Company

• Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar FibromatosisCompletedNCT05152173Phase 2

  Sponsor listed in the registry: Endo USA Inc., a Keenova Therapeutics Company

• A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)CompletedNCT06169319Phase 2

  Sponsor listed in the registry: Endo USA Inc., a Keenova Therapeutics Company

• StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal BurnsTerminatedNCT04765202Phase 1/2

  Sponsor listed in the registry: Stratatech, a Mallinckrodt Company · First submitted after Stratatech became part of Keenova Therapeutics plc

• Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar FibromatosisCompletedNCT05254457Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• StrataGraft Safety, Tolerability and Efficacy in Pediatric SubjectsCompletedNCT05517902Phase 3

  Sponsor listed in the registry: Stratatech, a Mallinckrodt Company · First submitted after Stratatech became part of Keenova Therapeutics plc

• A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With HypogonadismCompletedNCT04456296Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the ButtocksCompletedNCT05419505Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's ContractureTerminatedNCT05877066

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's DiseaseTerminatedNCT05873595

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Topical Lidocaine Patch in Low Back PainCompletedNCT00904540Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back PainCompletedNCT00904020Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual MigraineCompletedNCT00475514Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Vantas Implant Retrieval StudyCompletedNCT01013025

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Study of Histrelin Subdermal Implant in Patients With Prostate CancerCompletedNCT01394263Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)CompletedNCT04381117

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain ConditionsCompletedNCT00904202Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute PainCompletedNCT00226395Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant PainCompletedNCT00226421Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate CancerCompletedNCT01697384Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant PainCompletedNCT00225797Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) HeadachesCompletedNCT01035983Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual MigraineCompletedNCT00644033Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )CompletedNCT04123548Phase 3

  Sponsor listed in the registry: Stratatech, a Mallinckrodt Company · First submitted after Stratatech became part of Keenova Therapeutics plc

• Safety and Efficacy of EN3835 in Participants With Frozen ShoulderCompletedNCT04496167Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)CompletedNCT03526549Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Injection Techniques of Collagenase Clostridium Histolyticum (CCH) for the Treatment of EFP (Cellulite)CompletedNCT03632993Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock CelluliteCompletedNCT04677712Phase 4

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Acthar Gel in Participants With Pulmonary SarcoidosisCompletedNCT03320070Phase 4

  Sponsor listed in the registry: Mallinckrodt

• Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With LaxityCompletedNCT05249257

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Long-term Follow-up Durability (Efficacy) Study of EN3835 for the Treatment of AC of the Shoulder (Frozen Shoulder)TerminatedNCT04680156

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With TerlipressinCompletedNCT01143246Phase 3

  Sponsor listed in the registry: Mallinckrodt

• Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1CompletedNCT02770716Phase 3

  Sponsor listed in the registry: Mallinckrodt

• CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection TechniquesCompletedNCT04580303Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Histopathology Following CCH InjectionCompletedNCT04236635Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Real World CCH Study in Adult Females With CelluliteCompletedNCT04170296Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsTerminatedNCT02687451Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult WomenTerminatedNCT04209530Phase 2

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain FunctionWithdrawnNCT04128462Phase 3

  Sponsor listed in the registry: Mallinckrodt

• OCR002-SP103 - Oral Immediate Release StudyCompletedNCT03846843Phase 1

  Sponsor listed in the registry: Ocera Therapeutics, Inc. · First submitted before Ocera Therapeutics, Inc. became part of Keenova Therapeutics plc

• Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)CompletedNCT01966419Phase 2

  Sponsor listed in the registry: Ocera Therapeutics, Inc. · First submitted before Ocera Therapeutics, Inc. became part of Keenova Therapeutics plc

• Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric SubjectsCompletedNCT01210352Phase 3

  Sponsor listed in the registry: Endo Pharmaceuticals · First submitted before Endo Pharmaceuticals became part of Keenova Therapeutics plc

• Impact of Acthar on Everyday Life of Participants With Severe KeratitisCompletedNCT04169061Phase 4

  Sponsor listed in the registry: Mallinckrodt

• Acthar for Treatment-Resistant or Treatment-Intolerant ProteinuriaCompletedNCT02633046Phase 4

  Sponsor listed in the registry: Mallinckrodt ARD LLC · First submitted after Mallinckrodt ARD LLC became part of Keenova Therapeutics plc

• StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin DefectsTerminatedNCT03005054Phase 2

  Sponsor listed in the registry: Stratatech, a Mallinckrodt Company · First submitted after Stratatech became part of Keenova Therapeutics plc

• Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)TerminatedNCT03656692Phase 4

  Sponsor listed in the registry: Mallinckrodt

• Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 DiseaseCompletedNCT01747135Phase 1

  Sponsor listed in the registry: Vtesse, LLC, a Mallinckrodt Pharmaceuticals Company · First submitted before Vtesse, LLC became part of Keenova Therapeutics plc

• MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)CompletedNCT03712280Phase 2

  Sponsor listed in the registry: Mallinckrodt